NCT02265536View on ClinicalTrials.gov

A Study of LY3022855 In Participants With Breast or Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 1, 2015

Primary Completion Date

November 3, 2017

Study Completion Date

November 3, 2017

Conditions
NeoplasmsNeoplasm Metastasis
Interventions
DRUG

LY3022855

Administered IV

Trial Locations (2)

10065

Memorial Sloan Kettering Cancer Center, New York

90048

Cedars Sinai Medical Center, Los Angeles

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02265536 - A Study of LY3022855 In Participants With Breast or Prostate Cancer | Biotech Hunter | Biotech Hunter